Initial clinical evaluation of indigenous (90)Y-DOTATATE in sequential duo-PRRT approach ((177)Lu-DOTATATE and (90)Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, (90)Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects

(177)Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) alone has lesser potential in the clinical setting of neuroendocrine tumor (NET) with large bulky disease and nonhomogeneous somatostatin receptors (SSTR) distribution, owing to lower energy (Eβmax 0.497 MeV) and a shorter particle penetr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:World J Nucl Med
Main Authors: Parghane, Rahul V., Mitra, Arpit, Bannore, Trupti Upadhye, Rakshit, Sutapa, Banerjee, Sharmila, Basu, Sandip
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer - Medknow 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8034792/
https://ncbi.nlm.nih.gov/pubmed/33850492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/wjnm.WJNM_52_20
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados